Search clinical trials for: 60 µg/strain of Quadrivalent VLP Vaccine

Total 383 results

Medicago

Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Medicago

Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Medicago

Completed

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza

United States, Canada, Finland, Germany, Philippines, Thailand, United Kingdom
Medicago

Completed

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Medicago

Completed

Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Medicago

Completed

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada, Finland, Germany, Thailand
Suping Wang
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults (HIV)

Hepatitis B Vaccine
Suping Wang
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

Hepatitis B Vaccine
Shanxi Medical University
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination Among Drug Users

Hepatitis B Vaccination
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Icon Genetics GmbH
University Hospital, Ghent

Completed

Recombinant, Bivalent, Norovirus Vaccine Study

Norovirus

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age (QHD04)

Influenza

United States, Canada
Novavax
Department of Health and Human Services

Completed

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Influenza

United States
Merck Sharp & Dohme LLC

Completed

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

Papillomavirus Infections | Genital Diseases, Female
Medicago

Completed

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Influenza | Respiratory Tract Disease

Canada
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China

Cervical Cancer | HPV Infections | Precancerous Disease of the Cervix | HPV Related Diseases
Tan Tock Seng Hospital
Sanofi; A*Star; World Health Organization Collaborating Centre for Reference...

Recruiting

Immunogenicity Trial of 3 Influenza Vaccines

Influenza Vaccination

Singapore
Emory University

Recruiting

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Shanxi Medical University
Centers for Disease Control and Prevention, China

Completed

Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

Hepatitis B Vaccine
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Duke University
Boston Medical Center; Centers for Disease Control and Prevention; Children's...

Completed

Safety of RIV4 Versus IIV4 in Pregnant Women

Safety | Birth Outcomes | Adverse Event Following Immunisation

United States
Shanxi Medical University
Centers for Disease Control and Prevention, China

Not yet recruiting

Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population

Hepatitis B Vaccine

China
Pfizer

Completed

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Influenza, Human

United States, Brazil, South Africa, Philippines, New Zealand, Chile, Argentina
Shanxi Medical University
Centers for Disease Control and Prevention, China

Not yet recruiting

Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients

Hepatitis B Vaccine

China
Butantan Institute
InCor - Instituto do Coração - HCFMUSP.

Withdrawn

Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes

Rheumatic Fever
U.S. Army Medical Research and Development Command
U.S. Army Office of the Surgeon General

Completed

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Shigellosis

United States
Pfizer

Terminated

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Meningococcal Vaccine

Spain, Germany, Greece
Sanofi

Completed

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

Clostridium Infections

United States
Ihsan GURSEL, PhD, Prof.
The Scientific and Technological Research Council of Turkey; MonitorCRO; Nobel...

Completed

Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine (COVID-19)

Covid19

Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sinovac Biotech Co., Ltd

Completed

A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old

Seasonal Influenza

China
Sanofi Pasteur, a Sanofi Company

Suspended

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (QHD00014)

Influenza

United States
Green Cross Corporation

Unknown

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Influenza, Human
Ab&b Biotechnology Co., Ltd.JS
Henan Center for Disease Control and Prevention

Completed

A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months

Influenza

China
Hospital Israelita Albert Einstein
Ministry of Health, Brazil

Completed

Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes (VIP-ACS)

Acute Coronary Syndrome

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Influenza

United States, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Seqirus

Completed

Flucelvax (TIVc or QIVc) Pregnancy Registry

Pregnancy | Influenza, Human | Birth Defect

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Terminated

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Finland
Hvivo
GlaxoSmithKline

Completed

Development of an Intranasal Proteosome Influenza Vaccine

Influenza
Crucell Holland BV

Completed

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Influenza

Belgium
Sinovac Biotech Co., Ltd

Recruiting

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Recruiting

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Seasonal Influenza

China

Search clinical trials for: 60 µg/strain of Quadrivalent VLP Vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations